Report: Thursday, July 30, 2026, after market close
Conference call: Friday, July 31, at 8:00 a.m. ET (investors.irco.com)
The central question is not whether Ingersoll Rand can deliver another respectable quarter. It is whether organic demand and Industrial Technologies & Services margins are improving quickly enough to support the second-half acceleration embedded in management’s outlook.
Q1 showed the portfolio’s strengths—reported growth, a book-to-bill above 1x, strong Precision & Science Technologies performance, and ample balance-sheet capacity—but organic revenue was approximately flat and IT&S margins contracted sharply. Management has explicitly framed Q2 as an intermediate step: organic revenue should be roughly flat to slightly positive, consolidated margins should improve sequentially but remain 50–100 basis points below last year, and P&ST should continue expanding margins. (investors.irco.com)
A merely in-line quarter could therefore be acceptable if orders, IT&S margin progression, and the second-half commentary are constructive. Conversely, a headline EPS beat driven by tax or share count would carry limited weight if organic orders and core margins disappoint.
External estimates are not entirely consistent. A broader 12-analyst feed points to approximately $2.02 billion of revenue and $0.85 of EPS, while a smaller Zacks-derived sample carries $0.80 of EPS. The most useful working range is therefore roughly $2.0 billion of revenue and $0.80–$0.85 of adjusted EPS. (barchart.com)
| Metric | Q2 2025 actual | Q2 2026 reference point |
|---|---|---|
| Revenue | $1.888B | External consensus around $2.02B |
| Adjusted EBITDA | $509M | Roughly $511M–$538M from FY phasing |
| Adjusted EBITDA margin | 27.0% | Management indicated roughly 26.0%–26.5% |
| Adjusted diluted EPS | $0.80 | Approximately $0.80–$0.85 |
| Organic revenue | -3.4% | Flat to slightly positive |
| Free cash flow | $210M | Secondary to orders and margins this quarter |
The prior-year figures come from Ingersoll Rand’s Q2 2025 release. (s23.q4cdn.com)
The EBITDA and EPS ranges above are not formal quarterly guidance. They are calculated from management’s full-year ranges and its 46% first-half phasing assumption, less Q1 results. The same calculation implies Q2 revenue of approximately $1.92–$1.99 billion, although the company has described its phasing assumptions as approximate and acquisitions or currency can move reported revenue. (investors.irco.com)
Q1 reported orders rose 5%, but organic orders declined 1.9%. IT&S organic orders were down 2.6%, although management attributed about $40 million of delayed orders to Middle East projects and said underlying IT&S orders were approximately flat excluding that delay. P&ST organic orders grew modestly, with double-digit life-sciences orders offset by project timing elsewhere. (investors.irco.com)
The Q2 scorecard should focus on:
At its June investor conference, management continued to describe short-cycle trends as improving, China as stabilized, Europe as relatively steady, and long-cycle project delays as timing-related rather than cancellations. Approximately 40% of IT&S is aftermarket, while most remaining original-equipment revenue is short- to medium-cycle, with order-to-shipment times generally around 30–90 days. (stockanalysis.com)
There is a favorable external read-through: Atlas Copco reported a strong Q2, including sharply higher Compressor Technique orders, though part of that strength came from lumpy gas-and-process projects and should not be mapped directly onto IR. (atlascopcogroup.com)
IT&S represents roughly 80% of company revenue and produced a 26.7% adjusted EBITDA margin in Q1, down 210 basis points year over year. Management attributed the decline to organic volume pressure, tariff pricing that offsets tariff costs dollar-for-dollar but dilutes percentage margins, and continued commercial investments. (investors.irco.com)
For Q2, management effectively endorsed a consolidated margin decline of 50–100 basis points from last year’s 27.0%, primarily due to IT&S. That points to a total-company margin around 26.0%–26.5%, versus 25.4% in Q1. Management also agreed that IT&S margin modeling in the vicinity of 27.5%–28% was directionally reasonable. (stockanalysis.com)
A constructive result would include:
Management’s bridge to stronger second-half margins rests on four elements: improving organic volume, positive normalized price/cost, direct-material productivity, and restructuring benefits. It reiterated that bridge at the June conference. (stockanalysis.com)
This is also the principal execution risk. If Q2 IT&S margins fall below the expected range, the amount of improvement required in Q3 and Q4 becomes increasingly demanding.
P&ST delivered an excellent Q1:
Management expects another quarter of year-over-year P&ST margin expansion. Biopharma appears to be the healthiest part of the approximately $600–$700 million life-sciences platform, while IRX productivity and ILC Dover integration provide additional margin opportunity. (stockanalysis.com)
Investors should watch:
A P&ST margin below 30% or a sharp slowdown in life sciences would be a meaningful negative because this segment is expected to offset some of the near-term IT&S pressure.
Current 2026 guidance is:
| Metric | FY2026 guidance |
|---|---|
| Revenue growth | 2.5%–4.5% |
| Organic revenue growth | Flat to 2% |
| M&A contribution | Approximately 2% |
| Currency contribution | Approximately 0.5% |
| Adjusted EBITDA | $2.13B–$2.19B |
| Adjusted EPS | $3.45–$3.57 |
| FCF conversion | Approximately 95% |
Management maintained this outlook after Q1 and expected no significant full-year impact from the Middle East conflict or Section 232 tariff changes. (investors.irco.com)
Base case: Guidance is reiterated, potentially with updated FX and acquisition assumptions.
Bull case: Strong orders, P&ST performance, and better price/cost allow management to raise the lower end of adjusted EBITDA or EPS guidance.
Bear case: Guidance is maintained, but management becomes less confident about low-single-digit second-half organic growth or the timing of IT&S margin expansion. A nominal reiteration accompanied by weaker assumptions would likely be interpreted negatively.
The most important guidance detail is not necessarily the headline range. It is whether management still expects:
M&A remains IR’s preferred use of capital. At the June conference, management said it had closed four small transactions year to date, had ten additional bolt-ons under letters of intent, and continued to target 400–500 basis points of acquired annualized revenue during 2026. (stockanalysis.com)
Key questions include:
Recurring revenue is another underappreciated growth driver. Management said the initiative exceeded $450 million in 2025, up from roughly $200 million at the 2023 investor day, and continues to expand beyond North American compressors into Europe, Asia, blower, vacuum, and pump technologies. (stockanalysis.com)
At roughly $84–$85, IR trades near 24 times the midpoint of 2026 adjusted EPS guidance. The shares have recovered about 9% from the first trading day after Q1 earnings, when revenue missed external expectations and the stock declined. (fxempire.com)
That valuation leaves room for upside, but it also means investors are likely to demand evidence rather than another promise of second-half improvement.
The headline hurdle is manageable, but the quality hurdle is higher.
The best outcome would not simply be an EPS beat. It would be a quarter showing that short-cycle improvement is translating into organic orders, IT&S margins have begun their promised recovery, P&ST remains above 30%, and the second-half growth-and-margin ramp no longer depends primarily on management assurances.
Going into the print, the setup is balanced to modestly constructive: P&ST, recurring revenue, M&A, and improving peer demand provide support, while IT&S margin execution and the back-end-weighted outlook remain the principal risks.